Demonstration of the nutritional benefits of following an organic vs. conventional diets using “omics technologies”

Clinical effects of bioactive compounds from an organic vs. conventional diets (typical Mediterranean diet) in healthy and young subjects: A crossover randomized trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN29145931

Enrollment

Registered

2016-12-16

Start date

2016-06-20

Completion date

Unknown

Last updated

2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diet Nutritional, Metabolic, Endocrine

Interventions

Participants are randomised to one of two groups who consume each of the two study diets in a random order. There is a 1.5 month wash-out period between the two dietary interventions during which part

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Healthy volunteers 2. Males and females 3. Age: 18-40

Exclusion criteria

Exclusion criteria: 1. Previous history of cardiovascular disease (ischemic heart disease - angina or recent or old myocardial infarction, cerebral vascular accident, or peripheral vascular disease) 2. Homeostatic disorders 3. Any several chronic diseases 4. Hypertension or dyslipidemia 5. Study’s foods intolerance or allergic 6. Smoking subjects 7. Alcoholism 8. Other toxic abuse

Design outcomes

Primary

Measure	Time frame
1. Carotenoids in plasma and saliva is measured using HPLC-DAD at the start and end of each of the 28 day intervention periods 2. Bioavailability, identification and quantification polyphenols in stools, plasma, urine and saliva are assessed using LTQ-Orbitrap Mass Spectrometry and HPLC-MS/MS at the start and end of each of the 28 day intervention periods 3. Pesticides in plasma are measured using GC-MS at the start and end of each of the 28 day intervention periods	—

Measure

Time frame

1. Carotenoids in plasma and saliva is measured using HPLC-DAD at the start and end of each of the 28 day intervention periods 2. Bioavailability, identification and quantification polyphenols in stools, plasma, urine and saliva are assessed using LTQ-Orbitrap Mass Spectrometry and HPLC-MS/MS at the start and end of each of the 28 day intervention periods 3. Pesticides in plasma are measured using GC-MS at the start and end of each of the 28 day intervention periods

—

Secondary

Measure	Time frame
1. Adherence to the Mediterranean diet is measured using a questionnaire designed for the purpose of this study at the start and end of each of the 28 day intervention periods 2. Food intake is measured using food frequency questionnaires designed for the purpose of this study at the start and end of each of the 28 day intervention periods 3. Physical activity is evaluated with the Minnesota Leisure Time Physical Activity questionnaire at the start and end of each of the 28 day intervention periods 4. Urine metabolites (metabolomics) are assessed using LTQ-Orbitrap Mass Spectrometry at the start and end of each of the 28 day intervention periods 5. Markers of inflammation are measured by inmunnoassay on plasma samples at the start and end of each of the 28 day intervention periods 6. Constituency of gut microbiota is measured using LTQ-Orbitrap Mass Spectrometry on stool samples at the start and end of each of the 28 day intervention periods	—

Measure

Time frame

1. Adherence to the Mediterranean diet is measured using a questionnaire designed for the purpose of this study at the start and end of each of the 28 day intervention periods 2. Food intake is measured using food frequency questionnaires designed for the purpose of this study at the start and end of each of the 28 day intervention periods 3. Physical activity is evaluated with the Minnesota Leisure Time Physical Activity questionnaire at the start and end of each of the 28 day intervention periods 4. Urine metabolites (metabolomics) are assessed using LTQ-Orbitrap Mass Spectrometry at the start and end of each of the 28 day intervention periods 5. Markers of inflammation are measured by inmunnoassay on plasma samples at the start and end of each of the 28 day intervention periods 6. Constituency of gut microbiota is measured using LTQ-Orbitrap Mass Spectrometry on stool samples at the start and end of each of the 28 day intervention periods

—

Countries

Spain

Contacts

Public ContactRosa M Lamuela-Raventos

lamuela@ub.edu+34 934 034 843

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026